Patents by Inventor Ante Sven LUNDBERG

Ante Sven LUNDBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and Methods for Treatment of Duchenne Muscular Dystrophy
    Publication number: 20250064980
    Abstract: The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.
    Type: Application
    Filed: July 1, 2024
    Publication date: February 27, 2025
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ami Meda Kabadi, Chad Albert Cowan, Ante Sven Lundberg
  • CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses Thereof
    Publication number: 20250041349
    Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.
    Type: Application
    Filed: October 28, 2024
    Publication date: February 6, 2025
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ewelina Morawa, Tirtha Chakraborty, Ante Sven Lundberg, Tony Ho, Laura Sandler, Brenda Eustace, Jerome Rossert, Robert Kauffman
  • Materials and methods for treatment of hereditary haemochromatosis
    Patent number: 12186406
    Abstract: Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: January 7, 2025
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
  • CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
    Patent number: 12161674
    Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: December 10, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ewelina Morawa, Tirtha Chakraborty, Ante Sven Lundberg, Tony Ho, Laura Sandler, Brenda Eustace, Jerome Rossert, Robert Kauffman
  • COMPOSITIONS AND METHODS FOR GENE EDITING
    Publication number: 20240318200
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.
    Type: Application
    Filed: February 16, 2024
    Publication date: September 26, 2024
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan, Yvonne Sarah Aratyn
  • Materials and methods for treatment of Duchenne Muscular Dystrophy
    Patent number: 12053531
    Abstract: The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: August 6, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ami Meda Kabadi, Chad Albert Cowan, Ante Sven Lundberg
  • Materials and methods for treatment of hemoglobinopathies
    Patent number: 12043843
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 23, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Matthew Hebden Porteus, Melanie Ruth Allen, Chad Albert Cowan, Ante Sven Lundberg, Michelle I-Ching Lin, Jeffrey Li, Thao Thi Nguyen
  • MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A
    Publication number: 20240229078
    Abstract: The present application provides materials and methods for treating a patient with Glycogen Storage Disease type 1a (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.
    Type: Application
    Filed: January 8, 2024
    Publication date: July 11, 2024
    Inventors: Chad Albert COWAN, Roman Lvovitch BOGORAD, Ante Sven LUNDBERG, KIRSTEN Leah BEAUDRY
  • Materials and Methods for Treatment of Hemoglobinopathies
    Publication number: 20240226339
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting modulating or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: March 21, 2024
    Publication date: July 11, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-Ching Lin, Bibhu Prasad Mishra, Elizabeth Paik, Andrew Kernytsky, Todd Douglass Borland
  • MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
    Publication number: 20240175014
    Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.
    Type: Application
    Filed: December 14, 2023
    Publication date: May 30, 2024
    Inventors: Chad Albert COWAN, Roman Lvovitch BOGORAD, Jeffrey LI, Ante Sven LUNDBERG, Matthias Johannes JOHN, Jeffrey William STEBBINS, Thao Thi NGUYEN
  • Compositions and methods for gene editing
    Patent number: 11920148
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL3 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL3 gene in a cell by genome editing.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: March 5, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan, Yvonne Sarah Aratyn
  • MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS
    Publication number: 20240066150
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN10A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN10A gene in a cell by genome editing.
    Type: Application
    Filed: September 13, 2023
    Publication date: February 29, 2024
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Materials and methods for treatment of glycogen storage disease type 1A
    Patent number: 11866727
    Abstract: The present application provides materials and methods for treating a patient with Glycogen Storage Disease type 1a (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: January 9, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Ante Sven Lundberg, Kirsten Leah Beaudry
  • Materials and methods for treatment of alpha-1 antitrypsin deficiency
    Patent number: 11851653
    Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 26, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Jeffrey Li, Ante Sven Lundberg, Matthias Johannes John, Jeffrey William Stebbins, Thao Thi Nguyen
  • Materials and methods for treatment of pain related disorders
    Patent number: 11801313
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN10A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN10A gene in a cell by genome editing.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 31, 2023
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • MATERIALS AND METHODS FOR TREATMENT OF FRIEDREICH ATAXIA AND OTHER RELATED DISORDERS
    Publication number: 20230330270
    Abstract: The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.
    Type: Application
    Filed: January 30, 2023
    Publication date: October 19, 2023
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS
    Publication number: 20230279439
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.
    Type: Application
    Filed: October 3, 2022
    Publication date: September 7, 2023
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related Disorders
    Publication number: 20230227855
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with DMPK whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of DMPK gene in a cell by genome editing.
    Type: Application
    Filed: June 28, 2022
    Publication date: July 20, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Materials and Methods for Treatment of Duchenne Muscular Dystrophy
    Publication number: 20230181766
    Abstract: The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.
    Type: Application
    Filed: May 19, 2022
    Publication date: June 15, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ami Meda Kabadi, Chad Albert Cowan, Ante Sven Lundberg
  • Materials and methods for treatment of friedreich ataxia and other related disorders
    Patent number: 11564997
    Abstract: The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 31, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan